Dermal Filler Comparison Guide by Type, Area & Longevity

HA fillers remain the volume leader because they're reversible, predictable, and have the lowest barrier to entry. The key variable is crosslinking density: higher crosslink ratios (like Juvéderm Ultra Plus or Restylane Lyft) hold structure longer and resist diffusion, making them ideal for deeper folds and lips; lower crosslink densities (Juvéderm Volbella, Restylane Refyne) spread more naturally and suit fine lines and tear troughs. Allergan's Juvéderm line and Galderma's Restylane family dominate by volume and rebate leverage. Evolus' Kysse has carved a niche in lip work with its softer profile. HA typically lasts 6–12 months depending on placement and metabolism; lips and mobile areas shed faster. Cost per syringe ranges widely based on your loyalty tier—Allergan's Alle and Aspire programs, Galderma's Rewards, and Evolus' Rewards all offer volume-based rebates that can swing your net cost by 15–25%. Track your quarterly volume to hit tier thresholds; the difference between Tier 1 and Tier 3 often justifies inventory planning.

Biostimulators—PLLA (Sculptra) and **CaHA (Radiesse)**—trigger collagen remodeling rather than filling space directly. They last 18–24 months (Sculptra) or 12–18 months (Radiesse) and suit deeper structural loss, particularly midface and jawline. PLLA requires serial treatments (typically 3 sessions, 4–6 weeks apart) and patient education about delayed onset; Radiesse works faster and can be mixed with HA for immediate lift plus longevity. Acquisition cost is higher per syringe than HA, but amortized over 18+ months, the per-month cost is competitive. The skill floor is higher: improper placement or reconstitution of PLLA causes nodules; Radiesse's CaHA particles can migrate if injected too superficially. These are margin plays for practices with strong patient retention and the clinical chops to manage expectations. Radiesse has seen uptick in adoption post-GLP-1 boom (Galderma reported 25% aesthetics growth in H1 2026, partly driven by weight-loss-induced volume loss requiring structural support).

RHA (Resilient Hyaluronic Acid) represents a newer crosslinking chemistry designed to move with facial expression rather than resist it—marketed as more natural-looking in dynamic zones. Revance's RHA Redensity line includes dedicated products for undereye (RHA Redensity Eye, FDA-approved 2026) and lips, commanding a 10–20% price premium over standard HA. The clinical difference is real but subtle; adoption depends on patient willingness to pay and your ability to educate on the distinction. RHA is still ramping; Revance's market share remains small relative to Allergan and Galderma, but the undereye-specific indication is a differentiator for tear-trough practices. Pricing and rebate structures are still firming; check Revance's current loyalty program before committing volume.

Longevity varies dramatically by anatomic site and patient metabolism. Lips and perioral areas shed filler fastest (6–8 months for HA, 12–15 for biostimulators) due to constant movement and higher blood flow. Nasolabial folds and marionette lines hold 9–12 months (HA) or 18+ months (biostimulators). Cheeks and midface are ideal for biostimulators (18–24 months) because they're less mobile and benefit from structural support. Tear troughs and undereye are delicate; superficial placement with softer HA (Volbella, RHA Redensity Eye) lasts 8–10 months. Jawline and chin tolerate deeper, firmer fillers (Ultra Plus, Lyft) and hold 12–15 months. Matching filler to site reduces touch-ups and improves patient satisfaction. Track your re-treatment intervals by area and filler type; this data informs inventory and patient scheduling.

Net filler cost depends on three levers: list price (typically $600–$800 per syringe wholesale), volume rebates, and loyalty program tiers. Allergan's Alle platform offers quarterly rebates for hitting volume targets; Aspire is their higher-tier program with additional benefits. Galderma's Rewards program similarly tiered. Evolus (Kysse, Juvéderm Volux via partnership) runs Evolus Rewards. A practice doing 50 syringes/month might net $450–$550 per syringe after rebates; one doing 150/month could hit $380–$420. The math: if your average patient gets 2 syringes at $600 list, your gross margin swings from 25% to 45% based on rebate tier. Reconcile rebates quarterly and model your volume trajectory; if you're near a tier threshold, a small push in Q4 can unlock 6–12 months of better margins. Also track expiration dates; HA has a 3-year shelf life, but rebate programs sometimes incentivize buying ahead, which ties up capital.

A mature practice typically stocks 4–6 HA products (e.g., Volbella for lips, Refyne for fine lines, Ultra Plus for folds, Lyft for cheeks), 1–2 biostimulators (Sculptra for structural loss, Radiesse for mixed cases), and optionally 1 premium HA (RHA for dynamic zones). This covers 90% of patient requests without overextending inventory. Smaller practices should anchor on one HA family (Juvéderm or Restylane) and one biostimulator (Sculptra or Radiesse) until volume justifies breadth. Larger practices or those with strong biostimulator adoption may dedicate more shelf space to PLLA and CaHA. Stock rotation matters: HA expires, and rebate programs reward consistent volume, not hoarding. Plan quarterly inventory reviews tied to your rebate reconciliation. Also consider patient education materials—practices that clearly explain longevity, cost-per-month, and the difference between HA and biostimulators see higher acceptance of premium products and fewer complaints about filler "not lasting."

All fillers discussed here are FDA-cleared for their indicated uses (HA for wrinkles/folds, PLLA for facial lipoatrophy, CaHA for wrinkles/folds). Off-label use (e.g., HA for tear troughs, Radiesse for hands) is legal but requires informed consent and proper documentation. State scope-of-practice rules vary: some states require physician supervision for all injections, others allow nurse injectors under protocols. Verify your state's rules and your malpractice carrier's coverage for each filler type. Also note that hyaluronidase (Vitrase, Hylenex) is essential inventory for any HA-heavy practice—it reverses HA filler and is critical for managing overcorrection or vascular compromise. Stock it, train your team on its use, and document its availability in your consent forms. Biostimulators cannot be reversed, so technique and patient selection are paramount.

The GLP-1 weight-loss drug boom (semaglutide, tirzepatide) has reshaped filler demand: patients losing significant facial volume now seek structural fillers (PLLA, CaHA) rather than fine-line HA. Galderma's H1 2026 results showed 25% aesthetics growth, partly attributed to this trend. Allergan and Evolus are responding with expanded biostimulator portfolios and education. Revance's RHA Redensity Eye approval (2026) signals FDA's willingness to approve HA variants for specific anatomic indications, likely spurring competitors to follow. Expect continued fragmentation: more site-specific products, more premium positioning, and continued consolidation among manufacturers (AbbVie/Allergan, Galderma, Evolus, Revance). For practice owners, this means: (1) stay current on new clearances and indications, (2) negotiate rebates annually as competitive pressure shifts, (3) educate patients on the GLP-1 filler connection (many don't realize their volume loss is filler-responsive), and (4) consider biostimulator training if you haven't already—it's becoming table-stakes for mid-to-large practices.